THE DEVICES REMAIN IMPLANTED IN THE PT AND ARE NOT AVAILABLE FOR INSPECTION. PLEASE NOTE THAT THIS REPORT REPRESENTS TWO PRODUCTS WITH UNK CATALOG AND LOT NUMBERS. THIS FEMALE PT OF UNK AGE AND MEDICAL HISTORY EXPERIENCED A THROMBOTIC EVENT AND A MYOCARDIAL INFARCTION APPROXIMATELY TWO YEARS AFTER IMPLANTATION OF TWO CYPHER STENTS. THE INDICATION OF THE INDEX PROCEDURE WAS UNK. PERCUTANEOUS CORONARY INTERVENTION WAS PERFORMED IN THE RIGHT CORONARY ARTERY (RCA). DESCRIPTION OF THE VESSEL SUCH AS PERCENTAGE OF STENOSIS, TORTUOSITY, PRESENCE OF CALCIFICATION, ETC, WAS NOT REPORTED. VESSEL CLASSIFICATION WAS NOT REPORTED. BASELINE MEASUREMENT OF EJECTION FRACTION WAS NOT REPORTED. THERE IS NO INFO REGARDING PROCEDURAL DETAILS SUCH AS: DEBULKING OR PRE-DILATATION OF LESION BEFORE STENT DEPLOYMENT, PRE AND POST PROCEDURE CARDIAC ENZYME VALUES, PRE AND INTRA-PROCEDURE MEDICATIONS USED. TWO CYPHER STENTS OF UNK LENGTH AND DIAMETER, UNK LOT NUMBER AND UNK EXPIRATION DATE, WERE DEPLOYED AT UNK PRESSURE IN AN UNIDENTIFIED SECTION OF THE RCA. POST DILATION OF STENTS WAS NOT REPORTED. THE RESIDUAL DIAMETER STENOSIS WAS NOT REPORTED. CONFIRMATION OF COMPLETE STENT APPOSITION TO THE VESSEL WALL BY IVUS WAS NOT REPORTED. TIMI FLOW WAS NOT REPORTED. THE REPORT DID NOT INDICATE WHEN THE PT WAS DISCHARGED FROM THE HOSP. POST-INTERVENTION, PLAVIX WAS PRESCRIBED FOR 3 MONTHS. APPROXIMATELY TWO YEARS LATER, THE PT DEVELOPED ACUTE CORONARY SYNDROME WITH A HIGH-GRADE LESION AT THE SITE OF THE STENT. THIS WAS ALSO REPORTED AS LATE STENT THROMBOSIS, WHICH CAUSED MYOCARDIAL INFARCTION. TREATMENT INCLUDED ADD'L STENT PLACEMENT. NO ADD'L INFO WAS AVAILABLE. THE PRODUCTS REMAINED IMPLANTED IN THE PT AND ARE THUS, NOT AVAILABLE FOR EVAL. A DEVICE HISTORY RECORDS (DHR) REVIEW COULD NOT BE CONDUCTED BECAUSE THE LOT NUMBERS OF THE PRODUCTS WERE NOT REPORTED. THROMBOTIC EVENTS ARE A KNOWN POTENTIAL ADVERSE EVENT FOLLOWING STENT IMPLANTATION. PTS WHO ARE KNOWN TO BE AT HIGH-RISK FOR THROMBOTIC EVENTS INCLUDE THOSE WITH LONG LESIONS, A VESSEL DIAMETER LESS THAN 3 MM AND PREVIOUS THROMBUS. WITH SUCH LIMITED PT AND PROCEDURAL INFO AVAILABLE FOR REVIEW, THE LACK OF AVAILABILITY OF THE PRODUCT'S LOT NUMBER TO PERFORM A DHR REVIEW AND THE UNAVAILABILITY OF THE PRODUCT TO ANALYZE, IT IS NOT POSSIBLE TO DETERMINE WHAT FACTORS MAY HAVE CONTRIBUTED TO THESE EVENTS. PLEASE NOTE THAT THIS IS THE INITIAL/FINAL REPORT FOR THESE PRODUCTS.
